---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-070521"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2025-04-01T23:59:59+00:00"
generated_at: "2026-05-24T01:03:31.605668+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lyell Immunopharma to close West Hills facility, cut 73 jobs; CBO resigns

## Summary
- Board approved closure of West Hills manufacturing facility acquired from ImmPACT Bio in 2024.
- Workforce reduced by ~73 employees; expects $3M-$4M in severance costs in Q2/Q3 2025.
- LyFE center in Bothell, WA to manufacture IMPT-314 for clinical trials and potential launch.
- Matthew Lang (CBO) resigns effective April 13; will remain advisor until September 30, 2025.
- Reaffirms 2025 net cash use guidance of $175M-$185M; cash runway into 2027.

## SEC filing metadata
- accession: 0001193125-25-070521
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2025-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.05, 7.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000119312525070521/0001193125-25-070521-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000119312525070521/d920617d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-070521
- JSON: https://secwatch.observer/filing/0001193125-25-070521.json
- Plain text: https://secwatch.observer/filing/0001193125-25-070521.txt

## Key facts
- Executive change
  Matthew Lang resigned as Chief Business Officer at Lyell Immunopharma, Inc..
  - Action: resigned
  - Role: Chief Business Officer
  source text: On March 27, 2025, Matthew Lang, J.D. notified the Company of his resignation as Chief Business Officer and from all other offices of the Company, effective April 13, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000119312525070521/0001193125-25-070521-index.htm
- Restructurings & Charges
  Lyell Immunopharma, Inc. announced a restructuring with charges of $3.0 million to $4.0 million affecting West Hills manufacturing facility (approximately 73 employees).
  - Type: restructuring
  - Charge: $3.0 million to $4.0 million
  - Affected area: West Hills manufacturing facility
  - Headcount: approximately 73 employees
  source text: On March 31, 2025, Lyell’s Board of Directors (the “Board”) approved the closure of the West Hills manufacturing facility acquired as part of Lyell’s acquisition of ImmPACT Bio in 2024. The Board also approved the reduction of the Company’s workforce in West Hills by approximately 73 employees related to such closure. In connection with these actions, the Company expects to incur aggregate expenses of between $3.0 million to $4.0 million, related to severance, benefits, payroll taxes, and other workforce reduction costs, which are expected to be recognized primarily in the second and third quarters of 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000119312525070521/0001193125-25-070521-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.